Catalent Pharma Solutions, a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has commenced to expand its highly potent and cytotoxic clinical drug packaging capabilities within its 450,000 sq. ft. Kansas City, MO campus.

The expansion will increase the available packaging space for highly potent compounds adding two large packaging suites, a sampling lab, and space for various storage conditions. Segregated and separated from non-potent manufacturing operations, the new 6,000 sq. ft. facility is capable of handling SafeBridge Category 3, 4 and cytotoxic compounds. Completion is expected in January 2015.

Catalent already has several highly potent and cytotoxic drug packaging suites in its clinical supply facility in Bolton, UK, providing end-to-end clinical supply solutions from clinical supply management, comparator sourcing and primary packaging to storage and distribution globally.

“Customer demand for specialty clinical packaging has grown as the proportion of highly potent molecules in drug development pipelines increases,” commented Gerry Hepburn, chief operating officer, vice president and general manager of Catalent’s Clinical Supply Services business. “Industry-wide clinical packaging capabilities are insufficient to support future demand and this expansion will provide our customers with the necessary capacity and expertise to develop and commercialize potent and cytotoxic compounds.”